- iTransfuse Online Learning
- About us
- Contact us
- Site map
|Mother and baby|
Routine Rh(D) antenatal and postnatal prophylaxis are given to Rh(D)-negative women without preformed antibodies to Rh(D) using Rh(D) Immunoglobulin-VF.
Australia has been self-sufficient in its supply of Rh(D) immunoglobulin (Anti-D) since 31 March 2006.
This change represented Stage 3 and the final implementation phase of the routine Rh(D) Prophylaxis Program; including implementation for the recommended use for Rh(D) Immunoglobulin-VF in pregnant Rh(D)-negative women with no preformed Anti-D.
Administration of Rh(D) immunoglobulin to Rh(D)-negative women is important after each sensitising event. This reduces the incidence of devastating effects for the fetus and the newborn.
Sensitising events include normal delivery, miscarriage, termination of pregnancy, ectopic pregnancy, chorionic villus sampling, amniocentesis, abdominal trauma, antepartum haemorrhage or external cephalic version.
The Blood Service ceased to routinely issue WinRho SDF™. A quantity of intravenous Rh(D) immunoglobulin will be available in some circumstances where access to an intravenous Rh(D) immunoglobulin preparation is warranted. Contact the Blood Service for more information.
A range of Stage 3 educational support materials are available for download or to order free of charge.